Elevated levels of serum urokinase plasminogen activator predict poor prognosis in hepatocellular carcinoma after resection.

We conclude that uPA is a clinically relevant biomarker in HCC patients receiving curative resection, with higher expression of uPA being associated with higher mortality. This also highlights the potential utility of uPA as a therapeutic target for improved treatment strategies.